Q&A Genmab 2022-05-23
Aktiesnakken
Genmab
Zealand Pharma
NOVO
Q&A Zealand Pharma 2024-05-24
Bavarian Nordic
Shipping
Ennogie
TESLA
Amerikanske aktier
Grønne Aktier
Chemometec
Gubra
AMBU
Biotek-snakken
Smallcap og First North aktier
EL-BILER
Hansa Biopharma
Laks
Banker og Finans
ExpreS2ion
BITCOIN
Krypto
Medico
Pharma
23/5 13:02 af Jan Van de Winkel |
The data will be submitted for presentation at a future medical meeting, and, together with AbbVie, we will engage global regulatory authorities to determine next steps..
| |
23/5 13:01 af Jan Van de Winkel |
Last month, we and AbbVie announced topline results from the first cohort of the Phase 1/2 study of epcoritamab in patients with relapsed/refractory large B-cell lymphoma who have received at least two prior lines of systemic therapy, including 38.9% who received prior treatment with CAR T therapy. In these high-risk, heavily pre-treated patients, epco demonstrated an ORR of 63.1%, with a median duration of response of 12 months..
| |
23/5 13:00 af Jan Van de Winkel |
During the first quarter of 2022 we continued to build on our strong foundation to achieve our ambitious vision of transforming cancer treatment, with multiple advancements in our pipeline..
| |
23/5 13:00 af Jan Van de Winkel |
Sure..
| |
23/5 13:00 af Helge Larsen/PI-redaktør |
Can you give us a brief update on key figures and important events in Q1?
| |
23/5 12:59 af Jan Van de Winkel |
Thank you for inviting us to interact once more. We look forward to an energizing session with plenty of smart questions as always.
| |
23/5 12:59 af Helge Larsen/PI-redaktør |
Good afternoon Jan van de Winkel. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
| |
23/5 12:58 af Jan Van de Winkel |
Hello, yes we are online.
| |
23/5 12:57 af Helge Larsen/PI-redaktør |
Hi Jan van de Winkel. Are you online?
| |
23/5 12:30 af Helge Larsen/PI-redaktør |
Denne Q&A starter kl. 13.
|